Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer

Prostate

Volumn 72, Issue 7, 2012, Pages 789-802

  Vainio, Paula ^a,b   Wolf, Maija ^b,c   Edgren, Henrik ^c   He, Tao ^b   Kohonen, Pekka ^a,b   Mpindi, John Patrick ^c   Smit, Frank ^d   Verhaegh, Gerald ^d   Schalken, Jack ^d   Perälä, Merja ^b   Iljin, Kristiina ^a,b   Kallioniemi, Olli ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

aCGH; androgen receptor signaling; gene expression; gene silencing; prostate cancer cell growth

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ATP1B1 PROTEIN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DNA; DUTASTERIDE; ETHINYLESTRADIOL; FAM110B PROTEIN; FLUTAMIDE; GOSERELIN; LAS1L PROTEIN; MYC PROTEIN; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; YIPF6 PROTEIN;

ADVANCED CANCER; ANDROGEN DEFICIENCY; ANEUPLOIDY; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE PRODUCT; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC TRANSCRIPTION; GENOMICS; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; ORCHIECTOMY; PRIORITY JOURNAL; RNA INTERFERENCE; TRANSCRIPTOMICS;

ANEUPLOIDY; ANTIGEN PRESENTATION; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MALE; NUCLEAR PROTEINS; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SODIUM-POTASSIUM-EXCHANGING ATPASE; TRANSCRIPTOME;

EID: 84860338524     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21487     Document Type: Article

References (33)

1. Isaacs JT, Isaacs WB,. Androgen receptor outwits prostate cancer drugs. Nat Med 2004; 10 (1): 26-27. (Pubitemid 38524693)
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
3. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45. (Pubitemid 33741879)
4. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490. (Pubitemid 39315314)
5. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R,. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55 (19): 4438-4445.
6. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL,. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164 (1): 217-227. (Pubitemid 38364606)
7. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (6): 1665-1671.
8. Taichman RS, Loberg RD, Mehra R, Pienta KJ,. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117 (9): 2351-2361. (Pubitemid 47494332)
9. Dillard PR, Lin MF, Khan SA,. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295 (1-2): 115-120.
10. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T,. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69 (20): 8141-8149.
11. Attard G, Reid AH, Olmos D, de Bono JS,. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69 (12): 4937-4940.
12. Hauge H, Patzke S, Aasheim HC,. Characterization of the FAM110 gene family. Genomics 2007; 90 (1): 14-27. (Pubitemid 46900995)
13. Hauge H, Fjelland KE, Sioud M, Aasheim HC,. Evidence for the involvement of FAM110C protein in cell spreading and migration. Cell Signal 2009; 21 (12): 1866-1873.
14. Auffray C, Rougeon F,. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem 1980; 107 (2): 303-314.
15. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistic 2003; 4 (2): 249-264.
16. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi J-P, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S, Kallioniemi O,. Systematic bioinformatic analysis of expression levels of 17330 human genes across 9783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008; 9 (9): R139.
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J,. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5 (10): R80.
18. Smyth GK,. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
19. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T,. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153 (1): 141-148. (Pubitemid 28317516)
20. El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T,. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16 (1): 56-64.
21. Schmidt EV,. The role of c-myc in cellular growth control. Oncogene 1999; 18 (19): 2988-2996. (Pubitemid 29276538)
22. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70 (1): 100-112.
23. Albertson DG, Collins C, McCormick F, Gray JW,. Chromosome aberrations in solid tumors. Nat Genet 2003; 34 (4): 369-376. (Pubitemid 36935328)
24. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A,. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2010; 59 (4): 529-540.
25. Wang G, Wang J, Sadar MD,. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008; 68 (23): 9918-9927.
26. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M,. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138 (2): 245-256.
27. Negrini S, Gorgoulis VG, Halazonetis TD,. Genomic instability-An evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11 (3): 220-228.
28. Smyth MJ, Godfrey DI, Trapani JA,. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2 (4): 293-299. (Pubitemid 33706339)
29. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL,. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy. Urology 1995; 46 (5): 681-687.
30. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P,. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33 (4): 233-239. (Pubitemid 27524701)
31. Lee HM, Timme TL, Thompson TC,. Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60 (7): 1927-1933. (Pubitemid 30207654)
32. Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P,. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003; 3: 2.
33. Abdul M, Hoosein N,. Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 2000; 5 (4): 168-172. (Pubitemid 30408540)